New opportunity to improve diagnosis, care for people with cardiovascular-kidney-metabolic syndrome spr.ly/6015iejF3

A third of U.S. adults are at high risk for CKM syndrome. We are proud to launch an initiative with ACP American Diabetes Association American Society of Nephrology National Kidney Foundation STOPObesityAlliance & Cardiometabolic Center Alliance to standardize awareness, professional and patient education, and treatment of #CKMsyndrome.

Building on the fantastic science from the AHA, thanks to stellar leadership from Chiadi Ndumele Janani Rangaswami Katherine Tuttle , Sadiya Khan, Joshua J. Joseph, MD, MPH, FAHA Amit Khera Carissa Baker-Smith MD, MPH, FAHA, FACC, FAAP Bige Ozkan and so many amazing AHA volunteer experts!

Incredibly honored to be part of this major #ImpScience initiative from AHA Science ❤️

Very excited for yesterday's launch of the American Heart Association's new four-year Cardiovascular-Kidney-Metabolic Health Initiative, designed to enhance awareness, education, and treatment for individuals with CKM syndrome. spr.ly/6011ilATB

Janani Rangaswami Susan Quaggin Katherine Tuttle Alex Chang, MD, FASN, FAHA Stephen Juraschek MD, PhD, FAHA, AHSCP-CHS

Thoughtful write up by Tod Ibrahim for American Society of Nephrology about the future of nephrology. Perhaps #CKM health will be an anchor for the future 😊 Susan Quaggin AHA Science Katherine Tuttle Radhika Rajgopal Singh Deidra Crews, MD, ScM, FASN, MACP Chiadi Ndumele Kidney in Cardiovascular Disease

Carmen De Miguel, PhD, MS, FAHA Junie P Warrington, PhD, FAHA Camilla Ferreira Wenceslau Brandi Wynne, MS PhD FAHA Cam McCarthy Annet Kirabo D.V.M., M.Sc., Ph.D., F.A.H.A. Austin Robinson Lindsey Lab Dr Anastasia Mihailidou FAHA FCSANZ FESC Matthew Sparks, MD Swapnil Hiremath @[email protected] Tiago J. Costa Thiago Bruder 🚩 Justin P. Van Beusecum Mónica M Santisteban Georgina Gyarmati .Kidney in Cardiovascular Disease members! Tell us your favorite part of attending #hypertension2024! We love seeing the great research presented by all our members! Council on Hypertension How about you Laboratory of Vivek Bhalla, MD- Stanford Alexander Staruschenko Paul A Welling Janani Rangaswami Daria Ilatovskaya Oleg Palygin Andrew Michael South, MD, MS Rita Semenikhina??

Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression Highlighting epidemiological & therapeutic synergies between CKD & CV disease Cardio-kidney-metabolic #simpub for #ESCCongress in JACC Journals

Pooled data from ~15,000 pts in 4-RCTs examining the relationship b/w NT-proBNP, kidney function & outcomes in HFpEF Data which calls into question proposals for higher NT-proBNP references ranges in people with CKD #Simpub in JACC-HF for #ESCCongress sciencedirect.com/science/articl…

#FINEHEART pooled analysis of #finerenone phase 3 trials FINEARTSHF FIGARO FIDELIO - ~19000pts Muthu Vaduganathan European Society of Cardiology #ESCCongress #cardiokidneymetabolic ❇️ Non-significant ⬇️ in CV death (HR 0.89; p= 0.076) ❇️ significant ⬇️ all-cause death, HF 🏥, CV, AF/kidney events

🆕statement on evaluating & managing kidney dysfunction in patients with advanced heart failure. 📷Approach to assessment of kidney dysfunction in advanced HF ✍🏼@nishakidneydoc W. H. Wilson Tang, MD Janani Rangaswami Amy G. Fiedler, MD Modele Ogunniyi, MD, MPH @PietermartensMD James Fang Xingxing Cheng, MD MS @mbakitas

AHA Science statement on managing #kidney dysfunction in advanced #heartfailure in Circulation Kidney disease: vexing comorbidity that portends ⬆️risk in #HF but associated with GDMT cessation Optimizing #GDMT use, volume, perfusion can stabilize kidney fn pr.ly/6016WK51r

Delighted to work with this exemplary writing group on this statement from Kidney in Cardiovascular Disease AHA Science on kidney dysfunction in advanced #HF. Great leadership from W. H. Wilson Tang, MD Nisha Bansal MD

Study found sodium-glucose cotransporter-2 inhibitors (SGLT2i) improved kidney outcomes in cohorts with heart failure, CKD, and type 2 diabetes mellitus. Effects were consistent across patients w/ different combinations of these comorbidities @javedbutler1 bit.ly/JASN0491

Day 2 of #ESW2024 and we were hooked on Juan Carlos Q Velez giving his keynote speech! Next we’ll hear from Janani Rangaswami ! Pooja Amarapurkar Helbert Rondon, MD, MS, FACP, FASN, FNKF Pitt Renal PittDeptofMed Manisha Jhamb Rod Tan

Janani Rangaswami kicks off her cardiorenal syndrome talk with a 1949 reference to renal vein congestion in AKI 🤯#EastBySouthwest Univ of Pitt Center for Kidney Research Pooja Amarapurkar Christos Argyropoulos Helbert Rondon, MD, MS, FACP, FASN, FNKF

Congratulations to our team and redefining the vasodilation potential of intensive hemodialysis University Health Network Clinical Cardiovascular Physiology Laboratory Department of Medicine University of Toronto